EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

I-Chang Su, Yu-Kai Su, Syahru Agung Setiawan iD, Vijesh Kumar Yadav iD, Iat-Hang Fong iD, Chi-Tai Yeh iD, Chien-Min Lin iD, Heng-Wei Liu

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24097706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von I-Chang Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Taiwan University of Science and Technology, National Science Council of Taiwan, Taipei Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) is a highly heterogeneous disease with a mesenchymal subtype tending to exhibit more aggressive and multitherapy-resistant features. Glioblastoma stem-cells derived from mesenchymal cells are reliant on iron supply, accumulated with high reactive oxygen species (ROS), and susceptible to ferroptosis. Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM. The main interconnection between mesenchymal features, TMZ resistance, and ferroptosis are poorly understood. Herein, we demonstrated that a subunit of NADPH oxidase, CYBB, orchestrated mesenchymal shift and promoted TMZ resistance by modulating the anti-ferroptosis circuitry Nrf2/SOD2 axis. Public transcriptomic data re-analysis found that CYBB and SOD2 were highly upregulated in the mesenchymal subtype of GBM. Accordingly, our GBM cohort confirmed a high expression of CYBB in the GBM tumor and was associated with mesenchymal features and poor clinical outcome. An in vitro study demonstrated that TMZ-resistant GBM cells displayed mesenchymal and stemness features while remaining resilient to erastin-mediated ferroptosis by activating the CYBB/Nrf2/SOD2 axis. The CYBB maintained a high ROS state to sustain the mesenchymal phenotype, TMZ resistance, and reduced erastin sensitivity. Mechanistically, CYBB interacted with Nrf2 and consequently regulated SOD2 transcription. Compensatory antioxidant SOD2 essentially protected against the deleterious effect of high ROS while attenuating ferroptosis in TMZ-resistant cells. An animal study highlighted the protective role of SOD2 to mitigate erastin-triggered ferroptosis and tolerate oxidative stress burden in mice harboring TMZ-resistant GBM cell xenografts. Therefore, CYBB captured ferroptosis resilience in mesenchymal GBM. The downstream compensatory activity of CYBB via the Nrf2/SOD2 axis is exploitable through erastin-induced ferroptosis to overcome TMZ resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGlioblastomaAnimalsHumansMiceAntineoplastic Agents, AlkylatingCell Line, TumorDrug Resistance, NeoplasmNADPH Oxidase 2NF-E2-Related Factor 2Reactive Oxygen SpeciesTemozolomideSuperoxide Dismutase 2

Stichwörter der Autor:innen

CYBBSOD2erastinferroptosisglioblastomamesenchymaltemozolomide

Substanzen

Antineoplastic Agents, AlkylatingNADPH Oxidase 2NF-E2-Related Factor 2Reactive Oxygen SpeciesTemozolomideSuperoxide Dismutase 2CYBB protein, humanNFE2L2 protein, human

Autor:innen und Institutionen

  • Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
  • Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
  • Division of Neurosurgery, Department of Surgery, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
  • Taipei Neuroscience Institute, Taipei Medical University, Taipei City 11031, Taiwan.
  • International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
  • Department of Medical Research & Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.

ORCID-Profile: Syahru Agung Setiawan, Vijesh Kumar Yadav, Iat-Hang Fong, Chi-Tai Yeh, Chien-Min Lin

Förderung

  • National Taiwan University of Science and Technology
  • National Science Council of Taiwan
  • Taipei Medical University

Zitieren

APA

Su, I. C., Su, Y. K., Setiawan, S. A., Yadav, V. K., Fong, I. H., Yeh, C. T., Lin, C. M., & Liu, H. W. (2023). NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097706

Vancouver

Su IC, Su YK, Setiawan SA, Yadav VK, Fong IH, Yeh CT, et al. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097706

BibTeX
@article{Su2023,
  author = {Su, I-Chang and Su, Yu-Kai and Setiawan, Syahru Agung and Yadav, Vijesh Kumar and Fong, Iat-Hang and Yeh, Chi-Tai and Lin, Chien-Min and Liu, Heng-Wei},
  title = {NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24097706}
}
Kostenlos starten →